| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 17, 2025 | Dow closes more than 100 points lower after report says Trump seeks at least 15% tariff on EU imports: Live updates | The Dow Jones Industrial Average slid Friday after President Donald Trump reportedly pushed for greater tariffs on the European Union.
The 30-stock Dow fell 142.30 points, or 0.32%, settling at 44,342.19. The S&P 500 lost 0.01% after hi... |
| May 14, 2025 | BioCentury to Host Grand Rounds in Chicago: Where Translational Science Meets Investors and Dealmakers | Join VCs, academic innovators and biopharma executives to connect, collaborate and accelerate innovation at the forefront of drug R&D
CHICAGO–(BUSINESS WIRE)–May 14, 2025–
Top decision-makers from across the biopharma ecosystem will con... |
| Mar 3, 2025 | Circio´s leading position in circular RNA therapeutics highlighted by continued broad coverage in international life science industry media | Circio´s leading position in circular RNA therapeutics highlighted by continued broad coverage in international life science industry media
Mon, Mar 03, 2025 07:00 CET Report this content
More than 50 articles and interviews featuring Circi... |
| Jun 25, 2024 | Circio´s leading position in circular RNA therapeutics highlighted by broad recent coverage in international life science industry media | Circio´s leading position in circular RNA therapeutics highlighted by broad recent coverage in international life science industry media
Tue, Jun 25, 2024 07:00 CET Report this content
Circio´s position as a pioneering player in the rapidly... |
| Nov 3, 2023 | State Prescription Drug Affordability Boards could end up limiting access to the life-saving cystic fibrosis medication Trikafta | I was living on the precipice of end-stage disease when I enrolled in the clinical trial that resulted in the historically fast Food and Drug Administration approval for the game-changing cystic fibrosis drug Trikafta. Five years later, the... |
| Oct 2, 2022 | BMS was first but startup Sudo Bio aims to be best at blocking key autoimmune target | Immunology drug research has been casting about for better and safer ways to intervene in the inflammation driving autoimmune disorders. The recent FDA approval of a Bristol Myers Squibb plaque psoriasis drug made it the first approved prod... |
| May 10, 2022 | 'Front and center': Industry leaders call for response to Supreme Court abortion case draft | Biotech industry leaders want the drug development world to stand up and ensure employees have access to abortions after a draft ruling last week revealed the nation’s highest court might overturn a nearly five-decade-old ... |
| Sep 13, 2021 | Biotech's 'founding father' and influential deal broker Fred Frank dies at 89 | Frederick “Fred” Frank, legendary investment banker and biotech giant who reshaped the structure of the biopharma industry by brokering such influential deals as Roche’s initial purchase of Genentech stock in 1990, passe... |
| Sep 1, 2021 | 2 top FDA officials resigned over the Biden administration’s booster-shot plan, saying it insisted on the policy before the agency approved it, reports say | President Joe Biden. AP/Manuel Balce Ceneta
The FDA announced the resignations of Marion Gruber and Philip Krause on Tuesday.
The pair lead the FDA office in charge of approving vaccines.
Politico and Endpoints reported that the pair left i... |
| Jul 26, 2021 | Lumira Ventures Closes on US$255 Million of New Capital to Build Transformative Healthcare Companies | Oversubscribed Lumira Ventures IV to continue successful focus backing biotechnology and medtech companies in Canada and U.S. |
| Jul 23, 2021 | Patient advocacy organizations and FDA drug approval: lessons from Aduhelm | In the wake of last month’s controversial Food and Drug Administration approval of Biogen’s Aduhelm, Alzheimer’s Association CEO Harry Johns condemned the “negative voices” concentrating on the flaws in the FDA’s approval as “not pro-patien... |
| May 14, 2021 | Nine Square: Taking Aim at Organelle Function in Movement Disorders with Computation and Imaging (BioCentury Emerging Company Profile) | The Apple Tree-founded UCSF spinout is developing CNS-targeted small molecules against genetically defined targets
By Karen Tkach Tuzman
Republished with permission from BioCentury. Article originally published May 14, 2021
By combining ... |
| May 14, 2021 | Nine Square: Taking Aim at Organelle Function in Movement Disorders with Computation and Imaging (BioCentury Emerging Company Profile) | The Apple Tree-founded UCSF spinout is developing CNS-targeted small molecules against genetically defined targets |
| Feb 25, 2021 | Biden is looking beyond Woodcock or Sharfstein for FDA commissioner — report | Neither Janet Woodcock nor Joshua Sharfstein is likely to be nominated as the permanent FDA commissioner, Steve Usdin at BioCentury reports.
Janet Woodcock
The White House is looking for alternatives to Woodcock, the ... |
| Feb 13, 2021 | Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med | → Weeks after revealing that he’s leaving Eiger BioPharmaceuticals to join a private biotech, David Apelian has finally surfaced as CEO of BlueSphere Bio. Seeded by UPMC Enterprises to advance personalized treatments developed at the Univer... |
| Jan 6, 2021 | Covid-19 roundup: EMA recommends Moderna vaccine for authorization; Woodcock returns to FDA as Hahn advisor — reports | After delaying its decision earlier this week, the EMA announced it has formally recommended authorizing Moderna’s Covid-19 vaccine.
Regulators came to the decision Wednesday morning, marking the second vaccine ... |
| Dec 17, 2020 | 4 takeaways from FDA’s emergency vaccine reviews | After a grim and deadly year, and just in time for the holiday season, Americans finally have reason to hope.
This week, the U.S. government began delivering the first 2.9 million doses of BioNTech and Pfizer’s vaccine, with 20 million to b... |
| Nov 11, 2020 | Government gears for unprecedented challenge of Eli Lilly antibody rollout as efficacy questions linger | After months of anticipation, the FDA has authorized the first antibody treatment for Covid-19. Now what?
The US government faces a challenge unlike virtually any it has faced during or before the pandemic. They will ha... |
| Oct 22, 2020 | Protecting Biomedical Innovation as A National Security Asset | Full article from BioCentury
In recent years, it has become fashionable to focus on the high price of new treatments for certain cancers and rare diseases. Many observers ask why it is that U.S. citizens should subsidize the rest of the wo... |
| Oct 13, 2020 | The placebo response: a hidden risk to Covid-19 trials | The response to the Covid-19 pandemic by drug and vaccine developers has been swift. BioCentury lists more than 400 unique compounds — small molecules, antibodies, and vaccines — that are currently in clinical development for Covid-19.
Yet ... |
| Sep 16, 2020 | David Beier Op-Ed: Vaccine Hesitancy: Why American Values Matter | Link to full article from BioCentury
More than a third of Americans tell polls they would not take a vaccine to prevent COVID-19, the most devastating disease in 100 years. Vaccine hesitancy is even higher among Black people — hard-hit in ... |
| Aug 20, 2020 | The world desperately needs coronavirus treatments, even if we get a vaccine | Yuqing Liu/Business Insider
Hundreds of potential Covid-19 treatments have entered clinical testing in the last several months.
Some of those therapies are best suited to help during a certain stage of infection, while others target the bod... |
| Aug 20, 2020 | Seven PD-(L)1 players could be vying for a place on China's drug reimbursement list. How far will they go? | New updates to the process of assembling China’s latest National Drug Reimbursement List could mean that seven additional PD-(L)1 drugs will be covered by government-sponsored insurance schemes — but likely not without... |
| Jun 2, 2020 | Stephen Hahn: FDA will make some changes amid Covid-19 permanent | The FDA will look to permanently implement some of the processes and policies adopted in its response to the Covid-19 pandemic, FDA commissioner Stephen Hahn said during a virtual briefing hosted by the Alliance for a St... |
| May 27, 2020 | Beating Covid-19 will change how new therapies are developed | The global Covid-19 pandemic has left families and communities around the globe grieving for lost loved ones, exhausted from prolonged social isolation, and anxious about their financial future as unemployment reaches levels not seen since ... |
| Apr 17, 2020 | NIH corrals biopharma companies, regulators and trial networks to coordinate Covid-19 R&D | Francis Collins’ grand plan to bring order to the chaotic rush for Covid-19 vaccines and treatments is here.
The public-private partnership that the NIH director teased a few days ago will be known as ACTIV or Accelerating C... |
| Apr 8, 2020 | Keytruda nabs another priority review; Quell ties up CAR pact with Hannover Medical School | → Add another priority review for Merck’s Keytruda. Unlike most FDA submissions, this one comes not for a particular cancer type but for tumors with a particular biomarker, known as tumor mutational burden-high, or... |
| Mar 17, 2020 | Clinical trials for COVID-19 are expected to complete by the end of April | There is more good news this afternoon that the results from clinical trials for COVID-19 could start to roll in any day, with antimalarials coming through first, according to a report of BioCentury’s analysis of study completion dates in p... |
| Feb 26, 2020 | David Beier Op-Ed: We Need a Cheap Way to Diagnose Coronavirus | Link to full article from HBR
Covid-19, the new coronavirus, is on the verge of spreading across the world. Large clusters of cases are emerging outside China in South Korea, Italy, and Iran, and the Centers for Disease Control and Prevent... |
| Feb 5, 2020 | China researchers tout in vitro data for Gilead's antiviral against Wuhan virus — which they are trying to patent | There’s no definitive proof yet that Gilead’s remdesivir works as a treatment for 2019-nCov, but researchers in China clearly consider it promising enough to have applied for a patent on its use to combat the coronavirus viru... |
| Feb 4, 2020 | Regeneron joins the hunt for antibodies to fight a brewing pandemic as researchers whip up new trials for antivirals | Count Regeneron as the latest big biopharma company to pitch in on finding a therapy to combat the Wuhan virus.
Health and Human Services said on Tuesday that they’ll be working with Regeneron to use its antibody platfor... |
| Jan 22, 2020 | Wuhan virus outbreak triggers inevitable small-biotech rally | Every few years, a public health crisis (think Ebola, Zika) spurred by a rogue pathogen triggers a small-biotech rally, as drugmakers emerge from the woodwork with ambitious plans to treat the mounting outbreak. In most cases,... |
| Dec 23, 2019 | To make advanced therapies, we need to industrialize personalization | What’s the best way to measure the real rate of progress in personalized cell therapies, gene therapies, and other advanced therapies?
I’ve been tracking the ever-growing flow of reports about these therapies in scientific journals and pres... |
| Aug 30, 2019 | Azar keen on nominating Brett Giroir, divisive assistant HHS secretary, to top job at FDA — report | HHS secretary Alex Azar reportedly has his eye on nominating Brett Giroir — controversially confirmed as assistant secretary of HHS last year — to head the FDA as judgment day on Ned Sharpless’ term as acting commissio... |
| Aug 15, 2019 | On the cusp of PhI, Angelman-focused biotech scores potential buyout deal from Ultragenyx | Ultragenyx has found a new rare disease to devote itself to, roping in a young upstart as it begins a long trek to a new treatment for Angelman syndrome.
Their new partners at GeneTx is working toward an IND for GTX-102, an an... |
| Jun 21, 2019 | What Australian biotech needs to compete globally | Australia aims to be more than a destination for clinical trials, and an influx of cash is helping the country’s biotech sector fill its translational gap. But like other emerging biotech hubs, talent and a higher appetite for risk will be ... |
| Jun 7, 2019 | LabCorp selects its new CEO; Pfizer names ex-Genentech vet as new head of oncology R&D | Adam Schechter The Org
→ Longtime Merck executive Adam Schechter will be taking over as CEO and president of LabCorp with the retirement of David King on October 31— when he will become executive chairman of the board of d... |
| Apr 16, 2019 | Forget biosimilars. Peter Bach and Mark Trusheim believe price controls are the better way to rein in biologics prices | The proverbial social contract that drugmakers often cite to defend prescription drug prices hinges on the image of a patent cliff: After a period of exclusivity that allows developers to recoup R&D costs, any trea... |
| Feb 19, 2019 | As generic competition stutter sales of top oncology drugs, Roche secures speedy review for pair of experimental cancer offerings | As drug developers seek ways to expand therapeutic applications and overcome the hurdles seen with the first generation of antibody drug conjugates (ADCs), Roche is capitalizing on its trojan horse ADC — powered by... |
| Feb 13, 2019 | 5AM raises nearly $500M in two new biotech venture funds | According to Oct. 4, 2018 filings with the Securities and Exchange Commission, the total $350 million amount raised for 5AM Ventures VI is consistent with what the firm had sought to raise when it opened the fund. The filings for the Opport... |
| Feb 13, 2019 | Busy VC 5AM eclipses $125M target for fund to inject capital into existing portfolio, meets goal for sixth biotech fund | Last October, busy VC 5AM pencilled in a $350 million target for its sixth fund. On Wednesday, it was reported that the goal was met, and the venture group’s Opportunities I fund — designed to inject more cash into its exis... |
| Feb 8, 2019 | MorphoSys taps Bavencio lead for US operations; Two top FDA officials move to industry | → Having built out a commercial footprint in the US and led the launch of Bavencio for Merck KGaA, David Trexler is taking up a new role as president of German biotech Morphosys’ US subsidiary. Following a dual listing on the... |
| Jan 30, 2019 | It’s time to get serious about the economics of expanded access | As the winds of change blow away the lingering odors of the “right to try” miasma, it’s time to get serious about expanded access 2.0.
Last week, more than 500 people from industry, academia, government, and patient advocacy groups convened... |
| Jan 15, 2019 | In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica | BeiGene may have made its rep as a PD-1 pioneer in China, but it’s coming to the US with more cancer drugs in its arsenal.
The biotech $BGNE says its Bruton’s tyrosine kinase (BTK) inhibitor, zanubrutinib, now enjoys breakth... |
| Jan 11, 2019 | Ironwood recruits CMO on the eve of split-up; Roche vet Margrit Schwarz joins Genevant | → Ironwood Pharmaceuticals is filling up its C-suite to prepare for the impending split up into two entities. Just a week after tapping AstraZeneca’s Mark Mallon for the CEO job, the company has appointed Michael Shetz... |
| Jan 9, 2019 | The first patient has been treated under the controversial 'right to try' law | A patient diagnosed with an aggressive form of brain cancer became the first person in the US to access an experimental treatment under Right to Try. Signed into law by President Donald Trump in May 2018, it has been tout... |
| Oct 26, 2018 | Carving a pipeline out of troubled Teva, OrbiMed leads $60M launch of new NASH player | Teva $TEVA has had a rough year. Plagued by crippling debt, the Israeli generics giant has undergone a massive reckoning that culminated in an executive exodus and a reorganization of the business. Matters went fro... |
| Sep 14, 2018 | Hua Medicine reaps $110.5M, adjusting expectations for Hong Kong IPO | → Shanghai-based diabetes drugmaker Hua Medicine has concluded its Hong Kong IPO with a $110.5 million (HK$867 million) raise by pricing at the low end of its range. Now valued at $1.1 billion, Hua was the second company to... |
| Aug 1, 2018 | The bar lowers yet again for PRV prices, with Kyowa/Ultragenyx selling at $80.6M | Are we back where we started with the price tag of priority review vouchers? Their dwindling value slid further south this morning, with news that Kyowa Hakko Kirin and its partner Ultragenyx sold off their rare disease PRV fo... |
| Jul 9, 2018 | Abingworth raises $315M to place transatlantic biotech bets | Abingworth has raised a $315 million (€267 million) life sciences venture fund. The British VC shop will use the cash to continue placing bets on early to late-stage biotechs at home and abroad.
Sponsored by Agilent Technologies
How would y... |
| Jul 9, 2018 | Abingworth raises $315M to place transatlantic biotech bets | Abingworth has raised a $315 million (€267 million) life sciences venture fund. The British VC shop will use the cash to continue placing bets on early to late-stage biotechs at home and abroad.
The fund, ABV VII, will follow the same bluep... |
| May 23, 2018 | Astellas shedding 600-plus jobs as CEO shakes up R&D and sales ops in restructuring | Kenji Yasukawa
As Astellas president and CEO Kenji Yasukawa maps out a strategic plan for the company he’s just recently taken over, he’s also prescribed a round of restructuring with a goal to cut at least 600 employees... |
| May 8, 2018 | Ally Bridge Portfolio News – WUXI APPTEC PRICES A-Share IPO | Hong Kong and Shanghai, May 8, 2018 / BioCentury / – – Services and manufacturing company WuXi AppTec Co. Ltd. (Shanghai:603259) raised RMB2.3 billion ($354 million) through the sale of 104.2 million shares at RMB21.60 in an IPO underwritte... |
| Apr 26, 2018 | Pharmalittle: FDA probes safety of Parkinson’s drug; Koch brothers push new ‘right to try’ ads | Hello, everyone, and how are you this morning? We are doing just fine, thank you, courtesy of a warm and shiny sun enveloping the calm and quiet Pharmalot campus. Our short person has departed for the local schoolhouse and the official masc... |
| Apr 4, 2018 | With $340M crossover fund, Sofinnova Partners pivots to late-stage biotech investments while maintaining European focus | After years backing early-stage life science companies, Sofinnova Partners now has a crossover fund flush with $340.5 million (€275 million) to invest in both public and private players.
Jacques Theurillat
The Paris-based ven... |
| Feb 21, 2018 | Senior R&D exec Sue Dillon jumps ship at J&J, launches mystery biotech startup Aro with Centyrins tech | Two former executive heavyweights at Johnson & Johnson have left the pharma giant to launch a rather stealthy startup called Aro Biotherapeutics – and they are starting out with some drug tech they’re already closely fa... |
| Feb 15, 2018 | After a slapdown on Orkambi price, Vertex is dropping French trial sites while warning patients on access | Vertex Pharma $VRTX is playing hardball with French drug regulators — and cystic fibrosis patients waiting for their next-gen triple are getting caught in the middle.
Mired in a long-running dispute over the reimbursement... |
| Sep 8, 2017 | Wellington featured in BioCentury | RIG-GING AN EXIT: Rigontec takeout gives Wellington quick exit, momentum into new Fund. |
| Jun 14, 2017 | Pharmalittle: White House drafts order on drug prices, Express Scripts ends insulin discount deal | Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While ... |
| May 25, 2017 | Mystery biotech Emmaus grabs groundbreaking FDA panel backing for sickle cell drug — after quietly scrapping $225M deal | Yutaka Niihara
A little-known biotech out of Torrance, CA is one big step closer to winning the first new drug approval for sickle cell disease in close to 20 years. And it has achieved precious little attention for its years-... |
| Mar 10, 2017 | Gottlieb continues to be Trump's leading candidate for FDA; BeyondSpring completes unusual IPO | → Scott Gottlieb is President Trump’s leading choice for FDA commissioner, Bloomberg now reports, citing “people” familiar with the matter. BioCentury had the scoop in mid-February.
→ BeyondSpring, a biotech with deep ro... |
| Feb 20, 2017 | Trump in 30 Seconds Archive Nov. 2016 – Jan. 31, 2017 | advertisement
Tuesday, Jan. 31 A meeting on price
Pharma executives met with President Trump this morning to talk drug pricing, and he vowed to make it easier for smaller companies to compete. Trump also said he would streamline the drug ap... |
| Feb 17, 2017 | Gilead offloads a PhII-ready addiction therapy to an upstart which knows this drug well | Eight years ago, Gilead snapped up CV Therapeutics and its angina drug Ranexa for $1.4 billion, looking to beef up its portfolio of cardio drugs. But one of the assets it picked up, an ALDH-2 inhibitor dubbed GS-6637, never made... |
| Feb 8, 2017 | Pharmalot, Pharmalittle: Pharma execs expected to sign letter criticizing immigration restrictions | Good morning, everyone, and how are you today? We are doing swell, thank you, helped along by a bright, shiny sun enveloping the chilly Pharmalot campus, where the short person has left for the local schoolhouse and the official mascots are... |
| Feb 7, 2017 | GW touts positive survival benefit in small brain cancer study; Ablynx files for ultra-rare disease drug OK | • GW Pharma is touting claims that a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) produced positive survival benefits in a small study of 21 patients with recurrent glioblastoma multiforme, a common... |
| Feb 5, 2017 | The rise of femtech: women, technology, and Trump | The market is flooded with products tailored to the needs of men: viagra, penis enlargement pills, fitness apps, and more. But a new sector dedicated to women is emerging. Femtech, or female technology, is tickling the curiosity of hungry v... |
| Feb 5, 2017 | The rise of femtech: women, technology, and Trump | Did you miss a session from GamesBeat Summit 2022? All sessions are available to stream now. Learn more.
The market is flooded with products tailored to the needs of men: viagra, penis enlargement pills, fitness apps, and more. But a new se... |
| Jan 25, 2017 | Pharmalot, Pharmalittle: A hiring freeze may cause FDA review goals to slip | Top of the morning to you, and a fine one it is. A shiny sun is hovering over the Pharmalot campus as we approach the middle of the week. After all, this is an accomplishment and a celebratory cup of stimulation is in order to help us move ... |
| Jan 12, 2017 | Why that infamous LifeSci party might soon get women on boards | To his left is Kate Bingham, a managing partner at SV Life Sciences, who matches Rice’s enthusiasm and brings the necessary credibility. On the elevator on the way down, Bingham underscored Rice’s commitment. Like many others, she was skept... |
| Sep 26, 2016 | One upside to the drug price pressure debate: more biopharma deals | A downdraft in large cap biopharma revenues, followed by generalist investor malaise about the industry as a whole, would certainly drive away some of the capital in the space. Indeed, we’ve already seen the macro impact of negative pricing... |
| Aug 16, 2016 | Pharmalot, Pharmalittle: Vertex ends a late-stage cystic fibrosis study | Good morning, everyone, and how are you today? We are just fine, thank you, despite another steamy day unfolding here on the Pharmalot campus, where the short people and the official mascots are all sleeping in. As for us, we are quaffing c... |
| Aug 15, 2016 | Serving returns: How Ally Bridge expects to build on top of WuXi arbitrage play | China’s Ally Bridge Group hit the investment world’s radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with the listing of WuXi’s biologic... |
| Jul 19, 2016 | Celgene EVP Bagger gets a plum assignment on Trump team | BioCentury picked up a juicy bit of biotech-related presidential campaign news. Quoting sources, BioCentury says that Celgene EVP of corporate affairs Rich Bagger has taken a leave to work on Donald Trump’s transition ... |
| Jun 29, 2016 | What will separate the winners and the losers in the immuno-oncology R&D race? | But it does raise long term strategic and capital allocation questions for cancer R&D. This blog has raised this topic a few times in the past five years. In a 2012 post, The March of the Lemmings, the a huge amount of work on a small s... |
| Jun 13, 2016 | Pharmalot, Pharmalittle: First cholera vaccine is approved by FDA | Good morning, everyone, and welcome to another working week. We hope the weekend respite was exhilarating and refreshing, because that familiar routine of meetings and deadlines and growing to-do lists has now returned. But you knew this wo... |
| Jun 10, 2016 | Women demand more clout in biotech. First step? Take charge of the money | SAN FRANCISCO — There was a lot of talk this week at the global biotech convention here about rooting out sexism and bringing more women into the industry.
There were some signs of progress: No scantily clad “booth babes” to attract attende... |
| May 27, 2016 | Pharmalot, Pharmalittle: Feds probe three drug makers for links to charities | And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. And this will be a long weekend on this side of the pond, thanks to a holiday... |
| May 24, 2016 | Pharmalot, Pharmalittle: Pfizer syphilis treatment in short supply | Rise and shine, everyone, another busy day is on the way. And this is shaping up to be another cloudy one here at the Pharmalot campus. Nonetheless, our spirits our sunny. You know why. The Morning Mayor taught us long ago that every brand ... |
| May 12, 2016 | Morning Read: Larry Ellison donates $200M to set up cancer research center at USC, Theranos COO departs | Theranos President and COO Sunny Balwani has left the embattled diagnostic company, seven years after he joined to become the second executive after its founder Elizabeth Holmes. The company is under investigation from the U.S. Securities E... |
| May 6, 2016 | Morning Read: GSK nears approval of curative gene therapy for “bubble boy” disease | GlaxoSmithKline is thisclose to winning European approval for the first gene-replacement therapy to cure severe combined immunodeficiency, a deadly disease that leaves newborns unable to fight off infections. The condition is also referred ... |
| May 4, 2016 | Morning Read: Pfizer makes play for Medivation that could rival Sanofi’s bid, Shkreli may face more fraud charges | Former Turing Pharmaceuticals CEO Martin Shkreli could face additional securities fraud charges stemming from his work with Retrophin, federal prosecutors said. Additionally, Turing faces a lawsuit from Impax Pharmaceuticals over a breach o... |
| May 3, 2016 | Morning Read: Researchers identify milestone in breast cancer treatment | Johnson & Johnson faces more than 1,000 lawsuits after a woman successfully sued the company for $55 million after getting ovarian cancer from the company’s talcum powder — the second trial the company has lost over the issue this year.... |
| Apr 21, 2016 | Pharmalot, Pharmalittle: Allergan plans ad blitz for its double chin drug | Top of the morning to you, and a fine one it is here in Boston, where we are close to wrapping our latest trip to the corporate offices. We look forward to returning to the Pharmalot campus, of course, but meanwhile, we are as busy as ever ... |
| Apr 21, 2016 | Morning Read: Peter Thiel-backed Auris Surgical Robots acquires Hansen Medical for $80M | Medtronic voluntarily initiated a recall of nearly 10,000 battery packs for medical devices to monitor patients’ breathing after receiving reports of a defect that can cause heat damage. The battery packs are used for Covidien Oridion label... |
| Apr 6, 2016 | Morning Read: Researchers could gain access to HIPAA-protected data | Current law limits researcher access to treatment, payment or operations. But the Cures language isn’t included in bills to be marked up by the Senate HELP Committee. Supporters of the change, backed by groups like the Association of Clinic... |
| Apr 5, 2016 | Morning Read: Valeant slashes sales staff for women’s libido pill Addyi | For a cool $400 million upfront, Gilead Sciences just acquired a subsidiary of Cambridge-based Nimbus Therapeutics for its drugs that treat NASH, or non-alcoholic steatohepatitis, and hepatocellular carcinoma. The deal also includes up to $... |
| Mar 30, 2016 | Morning Read: FDA panel approves Acadia’s Parkinson’s disease treatment | Aveo Pharmaceuticals will pay $4 million to settle charges with the Securities and Exchange Commision, which accused the company of misleading investors about the FDA’s review of its cancer drug. — BioPharma DIVE
The Sandoz unit of Novartis... |
| Mar 28, 2016 | Pharmalot, Pharmalittle: Pharma plans a new tactic to lobby Congress | Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that relentless routine of meetings, deadlines, and whatnot has returned. And it has brought a spot of rain al... |
| Mar 23, 2016 | Morning Read: Obamacare faces contraception mandate in court, Merck wins case against Gilead | Merck won in its Hepatitis C patient case against Gilead. — BioPharma Dive
LIFE SCIENCES
Prediction: Bill Ackman will be a goat or hero over Valeant (and you’ll know which within six months). – Wall Street Journal
Bad news for AstraZeneca: ... |
| Mar 16, 2016 | Morning Read: Theranos set to host fundraiser for Hillary Clinton | “Today’s narrative about Theranos is that the company has focused more on its political relationships than on its core business, and that doing so created a hype that far exceeds the true value of the company’s products,” said Robert M. Wac... |
| Mar 11, 2016 | Morning Read: California changing legal smoking age to 21, GSK terminating deal with Five Prime Therapeutics | “These actions represent the strongest steps California has taken to fight tobacco use in nearly two decades,” Matthew Myers, the campaign’s president, said in a statement. “They will protect children from tobacco addiction, save lives and ... |
| Mar 2, 2016 | Morning Read: Olympus set to pay $623.2M in civil and criminal allegations | Looking for more HIMSS coverage? We have a separate HIMSS16 wrapup plus a dedicated daily newsletter with more news all this week.
LIFE SCIENCES
Gilead Sciences combination treatment for HIV has won FDA approval. The Odefsey could reach pea... |
| Feb 26, 2016 | Morning Read: Precision Medicine collaborations, Baxalta and Precision BioScience ink $1.7B CAR T deal | St. Joseph Health and its partner, Hart, will work with electronic health record vendors Allscripts and Meditech, to make patients’ data available through an API. It is intended to use health data to drive shared decision-making and persona... |
| Feb 22, 2016 | Pharmalot, Pharmalittle: Merck CEO says industry can do better, Pfizer shareholders may face large tax bills | Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating because that familiar routine of meetings, deadlines and whatnot has returned. You knew this would happen, yes? To cope... |
| Feb 12, 2016 | Pharmalot, Pharmalittle: layoffs at Aegerion, Valeant uses rare accounting tactic | And so, another working week is about to draw to a close. Not a moment too soon, yes? This is, as you may recall, our treasured signal to daydream about weekend plans. And this will be a long weekend on this side of the pond in order to cel... |
| Feb 5, 2016 | Pharmalot, Pharmalittle: Surge in biosimilars expected, Pfizer UK boss urges ‘radical reform’ | And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. And our agenda is rather modest. We hope to spend time with our ancestors and in... |
| Feb 3, 2016 | Morning Read: Valeant and Turing kill themselves with their own e-mails; CRISPR hits the public market with Editas’ $94M in IPO | Remember this phrase: “aggressive pricing through consultant recommendation.” – Wall Street Journal, STAT
Gene editing company Editas Medicine Inc. raised $94.4 million in an IPO through the sale of 5.9 million shares at $16, the low end of... |
| Jan 28, 2016 | Morning Read: Theranos’ most important 10 days in company history | This survey of our Newark, CA lab began months ago and does not reflect the current state of the lab. As the survey took place we were simultaneously conducting a comprehensive review of our laboratory’s systems, processes and procedures to... |
| Jan 27, 2016 | Morning Read: Why the medical industry should pay more attention to the Zika virus | LIFE SCIENCES
“Unexpected complications” led to Valeant CEO Michael Pearson’s lengthy hospital stay, but he is on the road to recovery. No word on a return date. – Wall Street Journal
The World Health Organization has posted a final version... |
